title: US Food and Drug Administration international collaborations for cellular therapy product regulation.
abstract: Cellular therapy products are an emerging medical product class undergoing rapid scientific and clinical innovation worldwide. These products pose unique regulatory challenges both for countries with existing regulatory frameworks and for countries where regulatory frameworks for cellular therapy products are under development. The United States Food and Drug Administration (US FDA) has a history of productive working relationships with international regulatory authorities, and seeks to extend this to the cellular therapy field. The US FDA and its global regulatory counterparts are engaged in collaborations focused on the convergence of scientific and regulatory approaches, and the education of scientists, clinicians, regulators, and the public at large on the development of cellular therapies.
authors.forename: Judith A
authors.initials: JA
authors.lastname: Arcidiacono
authors.forename: Joan W
authors.initials: JW
authors.lastname: Blair
authors.forename: Kimberly A
authors.initials: KA
authors.lastname: Benton
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000379:methods* / Q000592:standards*; D006801:Humans; D007391:International Cooperation; D014481:United States; D014486:United States Food and Drug Administration